Ev-AIFIB Preliminary Evaluation of the AIFib Software
Preliminary Evaluation of the AIFib Software in Real Time as a Medical Decision Aid for the Detection of Atrial Fibrillation Driver
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Lille, France
- Groupe Hopitaux Institut Catholique de Lille
-
Lyon, France
- Clinique de L'Infirmerie Protestante
-
Marseille, France, 13008
- Saint Joseph Hospital
-
Neuilly-sur-Seine, France
- Clinique Ambroise Paré, Neuilly
-
Nice, France
- CHU NICE Pasteur
-
Paris, France
- IHCPS Massy
-
Saint-Denis, France
- Centre de cardiologie du Nord
-
Toulouse, France
- Clinique Pasteur
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients 18 years of age or older
- Etiology in the following list:
- Atrial fibrillation for which a conventional anatomical approach alone (pulmonary vein isolation) is not performed: persistent AF, long standing persistent AF paroxysmal AF (redo), paroxysmal AF
- Atrial tachycardia de novo or secondary to AF ablation.
Exclusion Criteria:
- Contraindication to AF ablation
- Major bleeding disorder
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Software performance evaluation a posteriori
Time Frame: during the ablation procedure
|
real-time validation by the second operator of the correct detection of atrial fibrillation driver
|
during the ablation procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Indirect evaluation of the clinical effectiveness of the software
Time Frame: during the ablation procedure
|
AF stopping rate by removal of the areas detected by the main operator and the software
|
during the ablation procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HSJ_EvAIFIB_2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Software Performance Evaluation a Posteriori
-
NCT04814277CompletedSoftware Evaluation for Visualizing Anatomical Structures Not Typically Identified on Clinical MR Images
-
NCT02902328CompletedSoftware Evaluation for Visualizing Anatomical Structures That Are Not Typically Identified on Clinical MR Images
-
NCT03831282CompletedEvaluation of SpO2 Performance
-
NCT03570255CompletedEvaluation of SpO2 Performance
-
NCT02109484CompletedEvaluation of a Rotavirus Vaccine
-
NCT01455324CompletedEvaluation of a New Prosthetic Socket Liner Material
-
NCT01309347CompletedEvaluation of a New Prosthetic Socket Liner Material.
-
NCT01323465CompletedEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
-
NCT06979570TerminatedCountermeasure Evaluation | Neurocognitive Function | Psychological Factors | Performance Assessment | Sensory Science
-
NCT06666387CompletedThe Evaluation of a New MD - Combined PET-MR System
Clinical Trials on the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.
-
NCT04600245Recruiting
-
NCT05045131Completed
-
NCT06824142Recruiting
-
NCT00589784CompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial Hemangiopericytoma